Tolerability of the oral fluoropyrimidine S-1 after hand-foot syndrome-related discontinuation of capecitabine in western cancer patients. (3rd July 2017) - Kwakman, J. J. M.; Baars, A.; Boot, H.; Pruijt, J. F. M.; Winther, S. B.; Pfeiffer, P.; Punt, C. J. A.